A patient lies still while a machine photographs several thousand moles across her back and arms, one at a time, building a map no GP has time to draw by hand. An hour later she is sitting opposite a clinician who talks her through blood biomarkers, arterial function and body composition, then hands her a letter for her doctor flagging something worth a second look. The whole visit costs £299 and takes less time than most people wait for a routine GP appointment. This is the experience Neko Health has built in clinics across London, Manchester and Birmingham, and the one it is about to bring to Manhattan on the back of a fresh $700 million funding round that values the company at close to $7 billion, a fourfold jump from eighteen months ago.

The headline is a Silicon Valley-adjacent success story, backed by Spotify's Daniel Ek and a roster of celebrity investors. The more consequential story, for anyone watching the NHS, is what Neko already does once the scan is finished. It does not treat. It refers. Suspicious lesions, marginal biomarkers and borderline cardiovascular findings are written up and sent to the patient's GP, often triggering urgent referral pathways such as the two-week-wait route into NHS skin cancer clinics. The company bears no cost for what happens next. The NHS does. Reviewers of the service have already noted the resulting pressure on primary care from what one commentator called the worried well, patients arriving with results that are only marginally abnormal but still demand a GP's time and judgement to interpret.

None of this makes Neko a bad actor. Early detection genuinely saves lives, and the company's own figures suggest a meaningful proportion of clients are flagged for conditions that matter. But it does mean Britain now has a functioning, expanding, privately capitalised prevention system running in parallel to the NHS one, quietly annexing the diagnostic front end of care while leaving the NHS to absorb triage, treatment and the political credit for catching disease early. That the company's clinical leadership includes a former NHS England National Medical Director for Primary Care is a small but telling detail. Expertise built inside the health service is now being redeployed to build the pipeline that feeds referrals back into it.

This lands at an awkward moment for NHS strategy. Integrated care boards such as Greater Manchester are drawing up decade-long shifts toward prevention and community care, and national research funders are offering grants in the tens of thousands of pounds for prevention technology pilots in neighbourhood settings. Wes Streeting and now Yvette Cooper have made prevention and productivity central to their reform message. Set against a $700 million private raise attracting backers such as Mark Zuckerberg and Maria Sharapova, the scale mismatch is stark. The state is trying to build a prevention infrastructure on grant funding measured in tens of thousands of pounds while a single private company raises hundreds of millions to do a version of the same job for whoever can pay £299 and is willing to wait for an appointment slot.

The equity question follows naturally. Early detection delivered through a subscription clinic is early detection for people who can afford it and who live within reach of a handful of major cities. The NHS Health Check, by contrast, is free but limited in scope and interval, and increasingly looks like the basic public option sitting beside a premium private alternative that borrows the health service's own referral machinery when something goes wrong. If ministers are serious about prevention as a genuine shift rather than a slogan, they will need to reckon with a marketplace in which the diagnostic gains of early detection accrue disproportionately to the affluent, while the costs of follow-up, treatment and reassurance are socialised through an NHS that had no say in who was screened, for what, or how often. Neko's expansion into New York is a commercial story. Its continued growth in Britain is a policy one, and it is happening largely unexamined.